Defence Therapeutics Inc. (DTCFF)
OTC
Healthcare
Biotechnology
$0.45
▲ +15.01%
Market Cap
$26.3M
Sector
Healthcare
Industry
Biotechnology
Beta
1.39
52-Wk Range
0.3086-0.7787
CEO
Sebastien Plouffe
Country
CA
Currency
USD
Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biological/biosimilar therapeutic drugs for cancer and infectious diseases. Its proprietary platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. The company focuses on developing dendritic cell cancer vaccines; protein-based vaccine formulation against COVID and infectious diseases; and antibody drug conjugates (ADC) products targeting various cancers. The company was formerly known as Accum Therapeutics Inc. and change…
Open full interactive analysis & DCF →